Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning, everyone. Thank you for joining Mendus AB's Q2 2024 Business Update. My name is Eric Manning, CEO of Mendus AB, and today I'm joined by our Chief Medical Officer, Julian Rovers, and our CFO, Lotta FAM. As a summary of the second quarter of 2024, we raised roughly 69 million Swedish krona in April through the exercise of warrants that were associated with the financing that we carried out from 2020 through 2023. Sorry, with the participation from all major shareholders, management, and eligible board members. We're very happy with our current shareholder base and also with the fact that they all contributed to this part of the financing. We also had some board changes and importantly, a new chairman of the board in the person of Sven Andreasson. We're very happy that Sven was willing to step up to this role. He is someone with a very broad experience, both in Europe and the US, and has been on both sides of the pharmaceutical and biotech industries and brings a lot of business development expertise. So, we're happy with this new chairman. Very importantly, in the second quarter, we did a lot of immunological research on the samples we collected in the ADVANCE II trial. We presented those data at the CIMT and EHA conferences, and they confirmed proof of concept that Vididencel acts as an active immunotherapy in AML. We'll spend some time in the coming slides on what that exactly means. Also, very importantly, we announced in the first quarter a collaboration with the Australasian Leukaemia and Lymphoma Group (ALLG) and also received Ethics Committee approval to start the AMLM22-CADENCE trial, which is a combination trial with our product, Vididencel, and current standard of care in AML following the Ethics Committee approval. We immediately engaged in starting up the trial, which means that we shipped material to Australia, and we work with the clinical centers to make them ready for including patients in this trial. We'll provide an update in the coming slides. As a very important part, under the late-stage development strategy for Vididencel, we engaged in a manufacturing alliance with NorthX Biologics, which is a manufacturing organization based in Sweden. The reason it's so important is that we need to be ready for large-scale production to support our clinical trials going forward, and also in the end, for commercial launch, and you want that to be the same process. So, working with NorthX Biologics to establish a large-scale manufacturing facility and in the end, also large scale GMP manufacturing is something that is a very important pillar under our strategy. And we had in the first half of the year already completed the manufacturing facility, but now also performed the first large-scale runs, which we completed successfully as part of setting up this facility. We presented positive data from the Allison trial in ovarian cancer at the Small Organic Malignant Cancers Conference. We'll discuss those in detail. And also in July, we announced that we have established a collaboration with Institut Bergonié, which is a leading cancer center in France, to study our entire tumor program, primarily Vididencel, in soft tissue sarcomas. As financial highlights, we have a strong cash position of 130 million SEK, which provides us with a cash runway into the third quarter of 2025 based on current activities, which means also the activities we will discuss today. We had a relatively limited cash burn of 22 million Swedish kronor in the second quarter, and the reason it is lower than the net result is that the investments that we have made to establish the manufacturing, with the manufacturing aligned with NorthX Biologics have been prepaid. So they are, as we are progressing that alliance costs, but they don't weigh on our cash burn. Finally, we carried out a reverse stock split, which was resolved at the Annual General Meeting and effectuated in June. Moving to our lead program, Vididencel and AML. Acute Myeloid Leukemia, or AML, is a very aggressive blood cancer. The only way to treat it is with very intense chemotherapy. And also, there's hardly any cure. The only treatment that is potentially curative involves completely replacing the patient's immune system with a donor immune system. And that's called a hematopoietic stem cell transplant or bone marrow transplant. The biggest issue with AML is actually relapse due to residual cells. Patients who are unable to undergo a transplant are particularly susceptible to relapse. And that's related to residual disease or measurable residual disease. In short, MRD, and even after transplant, patients relapse; thus, relapse is also the main reason for transplant failure. Five-year survival rates are very low in AML, indicating a significant need for therapies that can maintain disease-free periods for these patients much longer than what is currently available. So we are developing Vididencel as an AML maintenance treatment. It's meant to provide longer periods of remission and overall survival. And also, very importantly, maintenance therapies should be able to deliver this without harming health or quality of life. There are currently no approved immunotherapies in AML. There is a significant impact from immune checkpoint inhibitors on solid tumors. It's a class of drugs that provides long-term survival benefits in a range of solid tumors, yet they have not been effective in bloodborne tumors. And that's why there's such a high medical need for new immunotherapies that could address this need for novel maintenance treatments. The ADVANCE II trial, as a summary, is a study involving 20 AML patients in their first complete remission after high-intensity chemotherapy yet still with measurable residual disease. We treat patients with six intradermal injections of Vididencel, and we conducted this trial with ten participating hospitals throughout Europe. The active study phase has already been completed, and patients are now in long-term follow-up. This is the data we last presented. It's at a median follow-up of 31.6 months. What you will appreciate is that a large group of patients is actually in long-term survival. Actually, the majority of patients are still alive in the long term. Follow-up and median relapse-free survival currently stand at two and a half years. What we have now performed in the last months and presented at the ESMO and EHA conferences is a much more detailed analysis of the immune responses following the end of treatment. And what we were able to show is that it has a very broad impact on the immune system. We had already, in previous presentations at conferences, shown that the product leads to T cell responses against specific tumor-associated antigens or WT1 prime REM in the majority of patients. So what we were now able to demonstrate is that, first of all, there is a difference between patients who respond very well to the treatment and patients who relapse despite the treatment. And that has to do with the baseline health of the immune system. But we were also able to show that the cell generally improves the immune status of patients. And finally, and this is the data we presented at EHA last June, we could show that those patients who have good immune responses, meaning T cell responses at multiple time points, and also above median levels of B cells. So, the cells that make antibodies. They were all in the long-term survival curve. And this is very important because it provides proof of concept that we did, indeed, activate Vididencel as an active immunotherapy in Acute Myeloid Leukemia, and that the immune responses are relevant because they result in long-term survival benefits. As a summary of that concept, it's important to understand the difference between active and passive immunity. Active immunity is something your own immune system builds up. It also comes with immunological memory, and it provides long-term protection against disease. It's very different from passive immunity, which you get from injecting antibodies or, for example, also immune cells that have been manufactured outside the body. They will deliver an immediate response, but they are not long-lasting. Now, the fact that we see after the initial treatment the broad immune responses associated with durable disease control in the majority of patients is proof of concept that we did indeed activate as an active immunity, leading to long-term immune protection. In this case, the majority of patients in the ADVANCE II trial. Currently, the only approved AML maintenance treatment is a drug called oral Azacitidine. It's a chemical drug. And what you see here is a picture from the registration trial, phase three trial for oral Azacitidine. And what you see is that there is a discrepancy between the placebo-treated group, the blue group, and the red group. So the Azacitidine-treated group. But it's a temporary difference. So the chemical drug slows down the disease but it doesn't cure it. There is an attractive side to Azacitidine, and this is documented in literature. But Azacitidine has an effect on cancer cells and makes them more immunogenic. And that is a good combination with immunotherapy such as Vididencel. And therefore, we expect the potential synergistic effect, uh, in the combination. And we've also seen initial promising data and our own preclinical work and also some initial positive data in our phase one trial. So there's a good basis to combine all the different aims of therapy and a big step forward. We have set up a collaboration with the Australasian Leukaemia and Lymphoma Group. Leukemia Lymphoma Group is a very renowned clinical research group. Uh, it's a big group of Australian and New Zealand-based, uh, but also a few Asian centers that are collectively called ALLG. They were also one of the leading research groups in the trial. We previously showed that our laser-sighted and approved, and they have already set up a large trial that allows companies, uh, to do research in combination with, um, with oral Azacitidine and this is now one of those companies that is working with ALLG. And we are combining Vididencel with oral Azacitidine in the AMLM22-CADENCE trial, or shortly, the CADENCE trial. The CADENCE trial has a two-stage trial design. Initially, we aim to open up nine clinical centers in Australia and treat 40 patients for an initial safety analysis of the combination therapy, and some oral Azacitidine, subject to a positive safety evaluation. That stage will be followed by another 100 patients for efficacy signals. This is a large trial. We're working with one of the best centers in the world. So, we're very happy that we've entered into this collaboration. And what I mentioned earlier, in the second quarter, we have been particularly focused on getting the trial up to speed. Following Ethics Committee approval, the clinical team and the regulatory team have worked closely with the hospitals, and the CMC team has ensured that the material is in Australia, ready to treat patients. And we expect the first sites to open in September. Now it adds up to a path to market that we are preparing for. So we have the monotherapy data, the proof of concept data from ADVANCE II. We are entering into the start of the AMLM22-CADENCE trial, and that will deliver a larger set of data in combination with the current standard of care, all as outlined. In parallel, we are preparing for pivotal stage development, since we want this product to be ready for pivotal stage development. We are currently in a preparation phase, which means that we are preparing the eventual registration trial protocol. We are also seeking regular feedback from the regulatory agency. So the EMEA or the EMA and the FDA, and we want this program to be translated into a clinical trial protocol by next year. In parallel, we are developing the large scale manufacturing. The manufacturing has to be there in order to not only support the trial but also in the end to allow for commercialization. And we are currently in the implementation phase of moving our process. That is a large scale manufacturing process we have developed at Mendus, with two of the manufacturing facilities at NorthX in Sweden. One of the other things we did in the first half of the year is extensive market research. We looked into the maintenance opportunity for Vididencel in Acute Myeloid Leukemia, using both public sources, but also a broad series of interviews with key opinion leaders. So doctors, experts in the field in both Europe and the U.S. We came to an estimate of an addressable market based on the current therapeutic setting of around 3.7 billion USD, and this is an indication that the market is sizeable. The reason is that the need for maintenance therapies is so broad and also that, so far, we have not seen any restrictions related to our products in the type of patients we can treat. So it's not limited to, for example, specific mutations. This is really a drug that can address the broader maintenance market and also comes with an attractive market opportunity. And then next to the current setting, which is after chemotherapy, there's also additional maintenance populations that we could address. And that includes the setting post-transplant. Also after transplant, relapse is actually the main cause of transplant failure in AML. And also there is a new group of patients which is not treated with high dose chemotherapy, but with a combination of Azacitidine and a new drug called venetoclax. And also those patients now have a better chance of achieving a first complete remission and would require maintenance therapy. So there's a broader market opportunity beyond the current already attractive market opportunity. So as a summary and outlook for the AML program, The proof of concept data, combining the survival data and immunomonitoring data, supports the mode of action of cells and active immunotherapy in AML. We are already in the process of expanding clinical development in combination with the current standard of care, as evidenced in the collaboration with ALLG and the first site of the AMLM22-CADENCE trial, which will open in September for patient recruitment. In parallel, we are preparing the registration trial protocol for Vididencel in AML, including feedback from regulatory agencies. This exercise is supported by an already strong regulatory dossier. And we are implementing large-scale manufacturing in our collaboration with NorthX Biologics. We should be ready for, let's say, entering the program into late-stage clinical sustainable development, which we can do by ourselves or in partnership to be ready by mid next year. The near-term milestones from the AML program include the survival update from the ADVANCE II trial that we expect to announce in the fourth quarter. We are still following up those patients in the long-term follow-up phase of the trial. The start of patient recruitment for the CADENCE trial, with the first sites opening in September. Moving to ovarian cancer as a general principle, we were interested to see if we could make Vididencel work as a product and an indication outside of AML, and we chose ovarian cancer because it's one of the deadliest gynecological diseases, primarily due to tumor recurrence. So the initial treatment, chemotherapy and surgery, is generally not enough to eradicate the disease completely. So together with the University Medical Center in Groningen, we've set up a trial with 17 ovarian cancer patients to see if we could trigger relevant immune responses in ovarian cancer. We provided an update on that trial in June at the ESMO Congress on Gynecological Cancers. The trial is fully recruited with 17 patients, and at week 22, the majority of patients that were treated, ten out of 17, still had stable disease. The other seven had image-confirmed recurrence. We're following up those patients now in the long-term follow-up to see the potential clinical benefit from the treatment. What we have established in the meantime is that Vididencel is triggering immune responses against a broad range of antigens that have been shown to be relevant for ovarian cancer. And the product also has a confirmed very good safety profile in this indication. So the part concerning immunogenicity and safety is very good. And we also aim to have the primary analysis based on the immunomonitoring data of all 17 patients in the fourth quarter of this year. Clinical benefits depend on the long-term follow up, and we will, of course, also provide updates on how that is progressing. As a summary, the safety and feasibility of Vididencel in ovarian cancer is confirmed already in the ongoing phase one trial, the Allison trial. The immunomonitoring data are positive. We are seeing tumor-directed immune responses in the majority of patients treated. Primary readouts in the fourth quarter, based on the immune evaluation of all treated patients and potential survival benefits, Depending on what we see in the long-term follow-up of these patients, which is ongoing, then shifting focus to Ilixadencel, It was a product that had already shown safety and signs of clinical efficacy in a broad range of hard-to-treat solid tumors. And we faced two challenges with the product: firstly, improving the manufacturing process, which we have successfully addressed. Secondly, we also needed to reposition the product. And the main reason, and that's a broader lesson learned for the field as a whole in the cancer immunotherapy field, is that it is very difficult to improve upon immune checkpoint inhibitors. As a class of drugs. Immune checkpoint inhibitors have made a significant impact on the cancer immunotherapy field. Then a lot of trials were performed to see if other immunotherapies could improve their efficacy, but that has not materialized. So, we need to think differently about how to approach solid tumors with immunotherapy. And what we have done with Ilixadencel, which is an intratumor primer, is we've basically learned all the lessons from the trials we have performed, which include both monotherapy data and data in combination with other drugs like tyrosine kinase inhibitors and checkpoint inhibitors. It's safe in those combinations. But we've also taken that other lesson into account, meaning we were focusing on tumors that are currently not responding to immunotherapies, specifically immune checkpoint inhibitors. And soft tissue sarcoma is one of those tumor types that is in that category and which could benefit from Ilixadencel as a means to engage the immune system in the treatment of those tumors in combination, potentially with other drugs. That was the background. We have been looking for a long time to conduct a high-quality trial with Ilixadencel to prove this concept in soft tissue sarcomas. And we've now taken a major step in the collaboration with the Institut Bergonié, which we announced last July. I will hand it over to our Chief Medical Officer, Aaron Rodgers, to describe in more detail the collaboration and the trial.
Yes, thank you, Eric. So it's a pleasure to be able to give a bit of background on the next clinical trial, which we are initiating in collaboration with a group of French cancer centers. So, they are collaborating in what we call a randomized trial. But I'll give you a bit of the background in the next slide. Again, soft tissue sarcoma. Just to reiterate what Eric was saying, one of these tumors is still very hard to handle. It's a rare type of tumor that typically arises from soft tissues such as fat, muscles, and blood vessels, and they are usually not discovered until a later stage. So often, they are already, say, metastasized, which makes them even more difficult to handle. When they're small, you can still resect them through a surgical procedure, for instance, or irradiate them. Unfortunately, the majority of these tumors are not, say, eligible for that. So, this cancer often recurs and is poorly responsive to the available therapies, such as chemotherapy. And it has also shown thus far to be poorly responsive to, for instance, immunotherapy. And so this is typically one of these indications where we feel that the international immunotherapy approach, which we are able to provide through Ilixadencel, might make a difference. So, we announced in mid-July. So just before the holiday period in most countries, we are initiating this collaboration with Institut Bergonié. This is an institute in Bordeaux, France. And I'll show you some of the details later. The collaboration means that we will add a cohort to an existing trial, which is run by Institut Bergonié and several other cancer centers in France. This is the regimen trial, and it's a phase one/two trial where they are combining already two existing and approved drugs in solid tumors, which are regorafenib, a tyrosine kinase inhibitor (TKI), and avelumab, which is an immunotherapy. So it's a checkpoint inhibitor, a PD-L1 inhibitor in this case specifically. As mentioned earlier, Institut Bergonié is one of the leading cancer centers in France. In this case, it's in Bordeaux. This trial is a multicenter trial. It's a collaboration of seven major French cancer centers, where they are recruiting patients for different indications into this regimen trial. In the trial, the intent is to see how the combination of a tyrosine kinase inhibitor and a checkpoint inhibitor might improve cancer treatment results. This trial is already supported by the providers of these two, namely, approved drugs. Regorafenib is provided by Bayer and Merck provides avelumab. This will facilitate the establishment of a cohort where we combine these three products. It actually means that they will be administered to soft tissue sarcoma patients twice, while they are also being treated with both the TKI regorafenib and the checkpoint inhibitor avelumab. We feel confident that the combination is feasible, based also on the fact that we have already previously conducted clinical trials where we combined ilixadencel with regorafenib, but also with a checkpoint inhibitor. The latest of which is the ADVANCE II trial, where we combined ilixadencel with a checkpoint inhibitor and showed that it's safe to have these two different immunotherapies work together. So in summary, for ilixadencel, as Eric already explained, we have conducted several clinical trials in the past and shown signs of clinical efficacy in typically some hard-to-treat solid tumors like renal cell cancer. We are now moving into the clinic again with ilixadencel to try to show the effect of ilixadencel in soft tissue sarcoma, which is also a very hard-to-treat tumor. The collaboration with Institut Bergonié will evaluate this combination. We will prepare in the next few months together with Bergonié for this trial to be approved so that we can start treating patients next year. I will now hand over back to Eric for the continuation.
Thank you. As concluding remarks, we now see the combination of the survival data and the immunomonitoring data as very important. Proof of concept, for example, in AML, where it provides a potential solution for a very high medical need for novel maintenance treatments. It's particularly important because it acts as active immunotherapy with a good safety profile that is able to deliver durable clinical responses in AML. That drives us to prepare the program for pivotal stage readiness. That will be an important catalyst for our corporate development, and that includes also the manufacturing side of things, but also, it's an important catalyst for potential opportunities. So for the registration trial, making sure we have the protocol ready and ensuring that the program is ready to enter that phase is currently top of our mind. The market research we performed in the first half of the year confirms the attractiveness of the AML maintenance market for Vididencel, and also there is potential to broaden that market potential by addressing additional AML maintenance populations. Additionally, our other pipeline programs, which include the ovarian cancer program and the ilixadencel clinical program we described today, as well as our pre-clinical NK cell program, are all well positioned to deliver additional upside. We have multiple milestones until the year end, including the survival update of the ADVANCE II trial, the long-term follow-up update of the patients in the trial, the start of patient recruitment in the AMLM22-CADENCE trial, and the primary analysis of the ESMO trial. But also in the background, of course, there's a lot more activity ongoing related to our manufacturing alliance and related to the preparations for the pivotal trial for ilixadencel. So with that, I would like to conclude the update and hand it over for Q&A.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ken Hanley from Perito Securities. Please go ahead.
Hi. Good morning and thanks for the business update. So, a few questions from me. Uh, can you tell us a bit more about the interaction you have with the regulatory authorities regarding the pivotal AML trial, and is there any clarity on the potential design and the number of patients? Okay.
Thanks. Chen. Uh, would you like to answer that question?
Yes, I think it's well-known, of course, that interactions with regulatory authorities are often a lengthy process. So, we are in the midst of that process. Thus, we cannot provide you with any outcome of the discussions held. The outcomes of these interactions with both the EMA and FDA will be known towards the end of the year.
Okay. Thank you. Uh, maybe another question. So, since you have shown a promising linkage between the cell triggering active immune responses and the survival benefits, can we expect this kind of immune response to be further studied in the CADENCE trial?
Yes.
That's correct. So the first part of the CADENCE trial will, of course, also include the immunomonitoring assays as we have performed also in the ADVANCE II study. And so we will definitely be able to compare the kind of immune responses we saw in the ADVANCE II trial, with the kind of immune responses we hope to see also in the combination with oral Azacitidine.
Okay. Perfect. Yes. Thanks for taking my questions.
Thanks for joining us, Jen.
The next question comes from Sara Mana from Edison Group. Please go ahead.
Hi. Uh, congratulations on your, uh, collaboration with the institute. Given that it's not a Mendus AB-sponsored study. Can we, uh, when can we expect to hear an update on the trial? And assuming that the data is supportive. What would the next steps for the program be?
Yes.. So, as indicated. Um, we will now start together with the whole process of gaining the necessary regulatory approval required for the amendment of the regulation trial with the inclusion of a cohort incorporating Ilixadencel. It's expected that this will take the rest of the year. And so, once the study is able to start recruiting patients, we will inform everyone that this will happen. But you're right. It's a study conducted by the institute in collaboration with additional cancer centers there in France. It's up to them to execute on this.
Let me add two elements to answer your question. First of all, I think what I'm trying to describe is the way we have repositioned it intentionally. We have had to adjust not only as a company, but also as a field, to the new reality, which is that immune checkpoint inhibitors have had a major impact in the treatment of solid tumors, and it's been very difficult to improve efficacy where they are effective. So we have to think very differently. That is the main goal of the soft tissue sarcoma arm, which we now want to include in the immune trial because the soft tissue sarcomas are not responding to checkpoint inhibitors by themselves. To see if the cell can bring that impact in this group of tumors will have, let's say, a broader effect on the way we see the possibilities for the product. And that is a major step in the direction of the development of Vididencel. And secondly, you're right, some of the trials we are conducting, particularly the CADENCE trial, the ALLISON trial, and also the REGULAR IMMUNE trial, are investigator-sponsored rather than company-sponsored. That makes them, first of all, very cost-efficient, but also there is a reason why we are able to work with these very renowned centers. These are all high-quality centers, and that's for all the trials we've been conducting. Both the ADVANCE II trials, which involved ten centers throughout Europe, and the LG trial, LG being one of the leading groups in oncology cancer research, are now also partnering with Institut Bergonié and other cancer centers, including institutions like, for example, the Gustave Roussy Institute. It's a broad group of centers, but they are very renowned and leading centers in cancer research. So the fact that these groups want to work with us also says something about the potential of the trials. So that's the other element of the collaborations we have set up.
Uh, yeah. That's great. And it sounds very promising. What's the rationale for participating in this very broad study? I think the combination arm was one of the 17 cohorts versus an exclusive trial. Are you considering any other indications at this stage?
Well, the long story short is we first need to deliver proof of concept of what we just described. Right. You want to do it in the most practical settings or with the most relevant combination of drugs available. This trial is sponsored by Bayer and Merck, featuring Regorafenib and Avelumab as a promising combination. And now we have the chance to demonstrate Ilixadencel. Denzel has an impact in that setting, so it's a very high-quality trial, and the fact that it's part of a broader trial, of course, makes it interesting for context. The most important part is that we can treat up to 43 patients, which is a significant patient population in such a rare indication like soft tissue sarcomas in this high-quality setting. The trial itself is very valuable. The trial that we are now setting up involves not only pediatric cancers and soft tissue sarcomas but also the broader context of the trial, including both the quality of the centers and the support from pharmaceutical companies, making this a high-quality setting to be part of.
Yeah. That's great. Thank you.
Thanks, sir.
The next question comes from Kristen Binder from Redeye. Please go ahead.
Hi. Thanks so much for taking my question. I just have one quick follow-up regarding immunity. I mean, you mentioned that it's a very resource-efficient way for you to gather some clinical data. Of course. But can you elaborate a bit more on how many resources you will need to dedicate to that trial? Is it just supplying an Ilixadencel cell, for example, or will there also be some financial commitment and how will it affect your burn rate and funding runway?
Yeah, like I said initially, this trial, as we've communicated previously, is part of our ongoing activities. So we had planned for this previously. So the statements we have made about our cash position and cash runway also include setting up and starting the REGOMUNE trial. Secondly, the investigator-sponsored trials are generally a very cash-efficient way to access a large data set without fully subsidizing it as a company. But it depends, of course, on the willingness of the other side to collaborate with us. So, it's a mutual commitment. And it means that we are supportive as a company. We need to deliver the drug. We're also working very closely with the centers involved to ensure that the hospitals are trained and they know how to treat patients with our products. Additionally, an important element, which we have also outlined for the ADVANCE II trial and which will be part of the AMLM22-CADENCE trial, is the immunomonitoring part. This is crucial for us in assessing the effectiveness of our product and will also be included in the immune trial. So the basic concept that we want to prove is that in clusters of tumors, and in this case specifically soft tissue sarcomas, where the immune system has difficulty locating the tumor. Ilixadencel can make the difference. So, as part of the trial, we will work closely with them to ensure that we can collect this kind of immunomonitoring data. And that is the way these collaborations work. And for the rest, yeah, we're just very proud we can work with these centers, and we're obviously very happy. We can do so much with relatively limited cash burn while generating valuable data for the company and for our products.
Perfect. Thank you so much. That was all from my side.
Thanks, Christine.
The next question comes from Anticipation from India. Please go ahead.
Taking my question. I wanted to first ask about how your understanding of the immune system's activation after this trial series is increasing. So, do you see a possibility to use this understanding for patient selection in the pivotal stage trial?
Well, generally speaking. And that's also the case with immune checkpoint inhibitors; if the product is safe, there is no reason to exclude patients. Right. Because you want to have the upside of the benefit. So point inhibitors, they are effective in only 10 to 20% of patients with responding tumors. But still, everyone uses them because the side effect profile of immunotherapies is so beneficial. And that is something which we also expect around 50 cases. The safety profile of the product is excellent. And the differences we have seen both at baseline and then also in the way the immune system builds up immunity after the end of treatment present a very clear pattern. But it's not black and white. It's not that you can definitively say this must happen, otherwise the patient will not respond. So generally speaking, both based on the safety profile and the fact that there is a bit of a gray zone between patients who will respond and those who will not, we anticipate a clear-cut outcome. It doesn't, at this point at least, make us go in the direction that we want to exclude patients outright. Um, maybe you only want to add to that.
No, I think you addressed the key points here. I think it's clear that we observe the connection between immune responses and survival. But currently, it doesn't allow us to pre-select patients, which might benefit from this.
So, I think the only thing we have seen on this, and this is a crucial principle, which I hope we also explained in the slides, is the mode of action of Vididencel and the positioning of our products, particularly the level of the disease. One important insight that we, along with the entire field, have gained is that cancer disrupts the immune system to the extent that activating it becomes very challenging. The best chance you have of boosting the immune system is actually when the disease burden is low. And that's also a consistent factor that we have seen in our clinical trials in AML.
Second question on the Allison trial and ovarian cancer. So did you see any correlation between immune responses and clinical outcomes?
Don't you want to comment on that?
Yeah, I think it's a bit too early to be able to comment on that because we are completing the initial evaluation of the immune responses for all 17.
Patients.
And to be able to see if there's a clear correlation with.
Uh, the.
Clinical benefit, we need to follow them up a little bit more. The majority of patients have to be followed up for, say, two years.
Years too.
Be able to have.
A more.
Solidify, say, a conclusion on whether it has an impact.
On the.
Clinical benefit.
Okay. Thanks.
Do you want to answer that, or should I answer it?
Yeah.
Go ahead if you want.
Yes, so this is what we expect, of course. Additionally, the broader context of the Ragamuffin trial reveals that there are benefits and synergies between different methods of influencing the immune system to combat cancer effectively. So there is an expected synergy. We have shown in our trials that Vididencel combines very well with both quieting times and immune checkpoint inhibitors. So, there is both a mechanistic approach and also.
The clinical experience has shown safety in the combination. Uh, a good question. Ultimately, it is very challenging to treat tumors when combining both kinase inhibitors and checkpoint inhibitors.
Okay. That's all for me.
Thank you, L.T.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
First and foremost, I'd like to thank everyone for joining us today. Also, the people listening in. We will be active in keeping everybody up to date. We're also looking forward to hosting more investor events in Sweden, where we will make some announcements shortly about the details. But, we're very happy to always be in touch with our investor base. I hope we have given you a good overview of the activities that are ongoing, both visible and those behind the scenes, where the company is at a very exciting stage of development. And thank you for continuing to support us.



















